|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<i>PAR-2</i> promotes cell proliferation, migration, and invasion through activating PI3K/AKT signaling pathway in oral squamous cell carcinoma.
|
31213575 |
2019 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
PIK3CA mutation incidence was significantly lower in adenocarcinoma (2/135, 1.5%) than in squamous cell carcinoma (5/77, 6.5%, p=0.0495).
|
16930767 |
2006 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PIK3CA amplification incidence was significantly higher in male, smoker and squamous cell carcinoma patients.
|
17681398 |
2007 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PIK3CA copy number gains were more frequent in squamous cell carcinoma (33.1%) than in adenocarcinoma (6.2%) or SCLC lines (4.7%).
|
18757405 |
2008 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PIK3CA amplifications in large cell and squamous cell carcinomas were significantly higher compared with adenocarcinomas.
|
23335533 |
2013 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutation was found in 3.9% of squamous cell carcinoma and 2.7% of adenocarcinoma.
|
24533074 |
2014 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA-mutated NSCLC represents a clinically and genetically heterogeneous subgroup in adenocarcinomas as well as in squamous cell carcinomas with a higher prevalence of these mutations in sqamous cell carcinoma.
|
25473901 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutations occurred more frequently in SCC than AC (25% vs. 11%, P=0.025), whereas KRAS mutations occurred more frequently in AC than SCC (24% vs. 3%, P<0.001) and ASC (24% vs. 3%, P<0.001).
|
26197069 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutations were more common in squamous cell carcinomas than in non-squamous cell tumors (15.3% vs 7.3%, of P < 0.01).
|
26358014 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations and amplification are detected in 1% of primary lung adenocarcinomas (ADCs) and in 38% of primary lung squamous cell carcinomas.
|
27007084 |
2016 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PIK3CA gene copy number increase is associated with a favorable clinical outcome in HPV-negative OPCs treated with surgery ± postoperative radiotherapy.
|
29714670 |
2018 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
PI3K inhibitors such as PI-103, PI-828 and PX-866 may be developed as potential therapeutic agents for effective treatment of oral squamous cell carcinoma (OSCC) patients, associated with activated PI3K/Akt pathway.
|
30519710 |
2019 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins.
|
23607916 |
2013 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activation of phosphoinositide 3-kinase (PI3K)/pAKT(Ser473) frequently occurs in advanced HPV-positive oropharyngeal SCC and elevated pAKT(Ser473) levels represent a feature during progression of oropharyngeal SCC, indicating a critical role of the mammalian target of rapamycin (mTOR) complex.
|
28945300 |
2017 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activity of the downstream PI3K effector protein kinase B (PKB) was higher in SqCas than in AdCas and was correlated with PIK3CA copy number (r = 0.75), suggesting that these copy number increases contribute to activation of PI3K signaling in SqCas of the lung.
|
12097266 |
2002 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adenosine induces intrinsic apoptosis via the PI3K/Akt/mTOR signaling pathway in human pharyngeal squamous carcinoma FaDu cells.
|
29616118 |
2018 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
After SCC transformation, the absence of G45 domain in DeltaG45 cells was associated with deficient extracellular signal-regulated kinase and phosphotidylinositol 3-kinase (PI3K) pathway activation, impaired invasion, deficient metalloproteinase activity, and absent tumorgenicity in vivo.
|
18413757 |
2008 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An increase in the copy number of PIK3CA, although small, was detected in 57.1% (8/14) of OSCC lines and 16.7% (18/108) of OSCC tumors using quantitative real-time PCR.
|
17052259 |
2006 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
An increase in the copy number of PIK3CA, although small, was detected in 57.1% (8/14) of OSCC lines and 16.7% (18/108) of OSCC tumors using quantitative real-time PCR.
|
17052259 |
2006 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Analysis of 675 tumors revealed activation of PIK3CA and other PI3K/AKT pathway genes in 31% of squamous carcinomas and 24% of adeno- and adenosquamous tumors, predominantly at two sites (E542K, E545K) in the helical domain of the PIK3CA gene.
|
26080840 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
|
17549376 |
2007 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Astaxanthin inhibits hallmarks of cancer by targeting the PI3K/NF-κΒ/STAT3 signalling axis in oral squamous cell carcinoma models.
|
31251469 |
2019 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.
|
25873175 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Common oncogenic mutations are infrequent in oral squamous cell carcinoma of Asian origin.
|
24224046 |
2013 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Computational analysis indicated that miR-296-3p targeted PTEN, which regulates the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway and PTEN is involved in the carcinogenesis of SCC. miR-296-3p directly regulated PTEN expression in head and neck cancer cells, with PTEN protein levels decreased in 4/19 the SCCs (21.0%), as compared with those in the IPs (76.4%).
|
28693263 |
2017 |